Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 24:9:3129.
doi: 10.3389/fimmu.2018.03129. eCollection 2018.

The Treatment of Giant Cell Arteritis in Different Clinical Settings

Alexander Pfeil  1 , Peter Oelzner  1 , Peter Hellmann  2
Affiliations
Review

The Treatment of Giant Cell Arteritis in Different Clinical Settings

Alexander Pfeil et al. Front Immunol. .

Abstract

This paper aims to raise awareness of the different disease courses, comorbidities, and therapy situations in patients with giant cell arteritis (GCA), which require a differentiated approach and often a deviation from current treatment guidelines. With the approval of tocilizumab (TOC), which specifically binds to both soluble and membrane-bound IL-6 receptor and inhibits IL-6 receptor-mediated signaling, the spectrum of available effective treatment options has been significantly broadened. TOC yields an extensive range of possible applications that go beyond a glucocorticoid-saving effect. In this context, the treatment of GCA is dependent on the disease course as well as the associated comorbidities. The different stages of GCA in association to co-morbidities require a detailed treatment strategy.

Keywords: clinical settings; comorbidity; giant cell arteritis; glucocorticoids; relapse; tocilizumab.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Different clinical settings during GCA treatment.
See this image and copyright information in PMC

References

    1. Aiello PD, Trautmann JC, McPhee TJ, Kunselman AR, Hunder GG. Visual prognosis in giant-cell arteritis. Ophthalmology (1993) 100:550–5. 10.1016/S0161-6420(93)31608-8 - DOI - PubMed
    1. Ciccia F, Rizzo A, Ferrante A, Guggino G, Croci S, Cavazza A, et al. New insights into the pathogenesis of giant cell arteritis. Autoimmun Rev. (2017) 16:675–83. 10.1016/j.autrev.2017.05.004 - DOI - PubMed
    1. Klein RG, Campbell RJ, Hunder GG, Carney JA. Skip lesions in temporal arteritis. Mayo Clin Proc. (1976) 51:504–10. - PubMed
    1. Gabriel SE, Espy M, Erdman DD, Bjornsson J, Smith TF, Hunder GG. The role of parvovirus B19 in the pathogenesis of giant cell arteritis: a preliminary evaluation. Arthritis Rheum. (1999) 42:1255–8. 10.1002/1529-0131(199906)42:6<1255::AID-ANR23>3.0.CO;2-P - DOI - PubMed
    1. Wagner AD, Gérard HC, Fresemann T, Schmidt WA, Gromnica-Ihle E, Hudson AP, et al. Detection of Chlamydia pneumoniae in giant cell vasculitis and correlationwith the topographic arrangement of tissue-infiltrating dendritic cells. Arthritis Rheumatol. (2000) 43:1543–51. 10.1002/1529-0131(200007)43:7<1543::AID-ANR19>3.0.CO;2-8 - DOI - PubMed

MeSH terms